Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic vomiting associated with
cannabis use. Our objective is to summarize the available evidence on CHS diagnosis …

Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric
infections and inflammatory conditions to disorders of motility, emesis and abdominal pain …

Over one hundred different phospholipid molecular species are known to be present in
mammalian cells and tissues. Fatty acid remodeling systems for phospholipids including …

Numerous side effects of synthetic drugs have caused medicinal plants to be regarded in
recent decades as a reliable source of new drugs. Regarding the analgesic effects of many …

The prevalence of obesity has been rapidly increasing worldwide over the last several
decades and has become a major health problem in developed countries. The brain …

BACKGROUND AND PURPOSE Cannabichromene (CBC) is a major nonpsychotropic
phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Orally administered synthetic
cannabinoids (nabilone and dronabinol) have been shown to be superior to dopamine …

Background: The G protein-coupled receptor 55 (GPR55) is a mammalian orphan receptor
that awaits a formal classification. There are an increasing number of reports directed to …

A multitude of physiological effects and putative pathophysiological roles have been
proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and …

Substance use disorders (SUDs) represent a significant public health crisis. Worldwide,
5.4% of the global disease burden is attributed to SUDs and alcohol use, and many more …